Navigation Links
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
Date:6/1/2008

macodynamic studies in mice, oral administration of XL184 resulted in balanced and durable inhibition of these targets. The compound has also shown activity against common mutant forms of RET and MET. XL184 has exhibited dose-dependent tumor growth inhibition and tumor regression in a variety of tumor models, including breast cancer, colon cancer, MTC, non-small cell lung cancer, and glioblastoma. A pivotal phase 3 trial of XL184 in patients with MTC is planned to begin in the summer of 2008. Phase 1/2 and 2 studies of XL184 in non-small cell lung cancer and glioblastoma multiforme are ongoing.

About Medullary Thyroid Cancer

The American Cancer Society estimates that MTC accounts for 5% of all thyroid cancers. MTC occurs in sporadic and inherited forms (approximately 80% and 20% of MTC, respectively), and is frequently associated with genetic activation of RET. The inherited form usually appears at a younger age, while dietary iodine deficiency and radiation exposure are risk factors for the sporadic form. MTC may metastasize to lymph nodes or other organs before it is ever diagnosed. Additionally, MTC does not take up radioactive iodine, which is commonly used to treat other types of thyroid cancers and to diagnose metastases. As a result, MTC is more difficult to treat than other thyroid cancers. There are no approved therapies for MTC; however, common treatments for MTC include surgery to remove malignant tissue, radiation therapy, and chemotherapy, all of which are associated with potential side effects, some of which may be long-term.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pip
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... SANTA MONICA, Calif. , Oct. 24, 2014 ... medtech leaders over friendly robotic competition at the  ... Conference on October 29-30 th at ... The event will highlight local student built robots ... and Technology" (FIRST) competition.  FIRST students and mentors ...
(Date:10/25/2014)... Oct. 24, 2014   Metanome, Inc. , a ... services and data analysis, was the genomic sequencing provider ... Phase I/II clinical trial of SER 109, an Ecobiotic® ... Clostridium difficile infections (CDI). Metanome has ... R&D and clinical programs. Such genomic characterization has enabled ...
(Date:10/25/2014)... HILL, N.C. , Oct. 24, 2014 /PRNewswire/ ... teams can provide a company access to diverse ... emerging markets, and round-the clock business hours for ... overcoming difficult hurdles. According to ... team disappointments, such as seeing a project not ...
Breaking Medicine Technology:Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 2Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 3Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2
... Amicus Therapeutics (Nasdaq: FOLD ) today announced ... No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods of ... isofagomine, the active ingredient in the Company,s investigational drug Plicera(TM) ... disease. The patent will expire in 2027. John ...
... CONFIRM SAFETY AND EFFICACY FOR ROOM TEMPERATURE STORAGENANTONG ... Bulletin Board: SNBP) is pleased to announce that ... skeletal muscle relaxant marketed as Kutai in China, ... multi-center Phase IV Clinical Study investigated the safety ...
Cached Medicine Technology:Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent 2Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent 3Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing 2Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing 3
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets for online ... Bob Seger & The Silver Bullet Band tickets for ... going on sale October 25 and are expected to ... the selection of tickets for Bob Seger & The ... is touring North America beginning next month, and he ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply to ... reduce the risks associated with the surgery, according to a ... stop the blood supply to the heart to be able ... the heart will reduce its ability to produce energy because ... flow to another large muscle, such as an arm or ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
(Date:10/22/2014)... October 22, 2014 On October 22, ... featuring skin diseases both fictional and real. The ... a nonprofit organization committed to advocacy and philanthropy in ... will take the opportunity to impart truth and clarity ... , There are many misconceptions about Morgellons Disease ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... clinical trials on a new investigational drug being developed ... been successfully completed. Completion of the initial phase ... prepared by researchers at Cardiff University,s Welsh School of ... an approved medicine have significantly improved. Approximately ...
... N.C. Millions of patients with advanced disease in palliative ... easily. But a new study from Duke University Medical ... intervention, and among those who do benefit, it doesn,t make ... just plain old room air both offer equal benefit. ...
... Reporter , THURSDAY, Sept. 2 (HealthDay News) -- An ... two hours, making only one doctor visit necessary before ... advance against a disease that kills nearly 2 million ... "This is a very important discovery," said infectious disease ...
... and a little serendipity led a Northwestern University research team ... used for gas storage and food and medical technologies. And ... first known all-natural metal-organic frameworks (MOFs) that are simple to ... the Northwestern MOFs you can pop into your mouth and ...
... Stem cells might be thought of as trunks in the ... can turn into a dazzling variety other cellskidney, brain, heart ... the capacity to turn into virtually any cell type in ... of cell therapies, the conquering of age-old diseases or even ...
... September, 2010 - Elsevier announced today the publication of ... Andropause Society (EMAS) in the journal Maturitas ... post-reproductive health of women. The statements cover the ... epilepsy, endometriosis and premature ovarian failure. Each statement ...
Cached Medicine News:Health News:First clinical trials successfully completed on potent new hepatitis C drug 2Health News:Study challenges value of oxygen therapy in end-of-life care 2Health News:Study challenges value of oxygen therapy in end-of-life care 3Health News:Experimental TB Test Called Fast and Accurate 2Health News:Experimental TB Test Called Fast and Accurate 3Health News:Edible nanostructures 2Health News:Edible nanostructures 3Health News:Study finds that cancer-causing gene crucial in stem cell development 2Health News:Study finds that cancer-causing gene crucial in stem cell development 3Health News:EMAS publishes position statements about the post-reproductive health of women 2
1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride, 7.5% Glycerol....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
Medicine Products: